Please note: The information displayed on this page might be outdated.
Oncimmune: Oncimmune's proprietary platform is underpinned by rapid biomarker discovery and a comprehensive immunogenic protein library of over 8,000 antigenic proteins. Oncimmune has a role in supporting case-selection, complementing diagnostic evidence, and facilitating therapeutic decision-making. Oncimmune's patented technology measures blood levels of autoantibodies to tumour-associated antigens, the combination of which is highly specific for target cancers, whose characteristic signal can be detected four years or more before standard clinical diagnosis.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, United Kingdom
Disease Space
Diagnostics, Immuno-Oncology, Oncology
Industry
Diagnostics
Listing
Europe, Public
Market Cap
<100MM
Website:
Address:
Clinical Sciences Building, City Hospital, Hucknall Road
Nottingham, NG5 1PB
United Kingdom

Company Participants at European Biotech Investor Day 2019

  • Adam Hill, Dr, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Oncimmune Holdings Plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Ruffer LLP 4.74 3,000,000 5.16 Stakes 2020-05-29
Miton Asset Management Ltd. 2.92 1,845,457 3.17 Funds 2020-03-31
Gabelli Funds LLC 0.01 4,000 0.01 Funds 2019-12-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.